Background: Breast cancer (BC) and skin cancer rates among Parkinson's disease (PD) 
Introduction
Breast cancer (BC) is more frequently diagnosed in patients with sporadic (1) and inherited forms (2) of PD than in the general population, yet the molecular basis for this association remains elusive. Given the involvement of PD predisposition genes in cell cycle, their reported functions as oncogenes and tumor suppressor genes (3) , and somatic involvement in BC tumorigenesis (e.g., 4), we hypothesized that the PD-BC association may be attributed to co-segregation and in linkage disequilibrium of BC and PD predisposition genes. To test this notion, we performed a focused literature search for single nucleotide polymorphisms (SNPs) that have been associated with BC predisposition through genome-wide association studies (GWAS) and assessed if they are overrepresented in chromosomal regions associated with inherited forms of PD.
Methods

Search Procedure
Database searches were carried out in PubMed (5) , GWAS catalog of the National Human Genome Research Institute (NHGRI) (6) , and the publication database of the Breast Cancer Association Consortium (BCAC) (7), to identify GWAS studies published until July 2012.
Inherited PD Genes and Chromosomal loci
The following PD predisposition loci were targeted: 1) PARK7 (OMIM# 602533), chromosome 1p36.23; 2) PINK1 (OMIM# 608309), chromosome 1p36.12; 3) SNCA (OMIM# 163890), chromosome 4q22.1; 4) PARK2 (OMIM# 602544), chromosome 6q25.2-q27; 5) LRRK2 (OMIM# 609007); chromosome 12q12.
Selection Criteria and SNP's
We searched peer-reviewed, English-language publications reporting GWAS analyses on all pathological types of BC cases and controls of all ethnicities. Publications assessing interactions between SNPs and other risk factors or BC mortality risk, and candidate gene based studies were excluded. Only results from GWAS replication stage with SNPs showing p ≤ 0.05 that localize to one of the four chromosomes of interest were considered. After removal of duplicates, SNPs located to the chromosomes of interest, were plotted using the NCBI Sequence Viewer 2.23 tool (8). The distances between each of the genes of interest and the identified SNPs on the same chromosome were calculated.
Results
Of 194 articles identified, 153 articles did not meet the selection criteria, and 14 did not report any chromosomally relevant SNP. The 29 articles that met all review criteria are listed in Table 1 . Overall, 188 BC associated SNPs located to one of the four "target chromosomes" were identified (Table 2) : 43 SNPs localize to chromosome 1 (minimal distance from PINK1 = 916,731 bps; minimal distance from PARK7 = 6,096,002 bps); 46 SNPs localize to chromosome 4 (minimal distance from SNCA = 3,606,769 bps); 72 SNPs localize to chromosome 6 (minimal distance from PARK2 = 1,654,718 bps); 27 SNPs localize to chromosome 12 (minimal distance from LRRK2 = 7,186,058 bps). None of the identified BC associated SNPs were located at genomic distance <500,000 bps from any of the analyzed PD genes.
Discussion
No BC-associated SNPs localized in the genomic proximity of PD predisposition genes found on chromosomes 1, 4, 6, or 12. Thus, the observed increased BC rates in inherited forms of PD cannot be accounted for by a simple co-segregation and shared genomic loci.
Despite the lack of association at the genomic level between BC SNPs and PD predisposition genes, other genetic or epigenetic mechanisms may still be operative. If BC results from the actions of multiple rare alleles, each one with a medium effect on BC risk, then the methodology used in GWAS would have missed these relatively rare sequence variants. This explanation seems less likely as there was no association reported between family history of BC and PD risk in a large US cohort (9). To assess this possibility, a whole exome-or even a whole genome-dataset of BC and PD cases should be queried, when it becomes available.
Another possible explanation for the BC-PD association may be epigenetic: miRNA's may be involved in promoting the expression of BC related genes and concomitantly, repress genes that are needed for normal dopaminergic function. Indeed, miR-7, which represses α-synuclein protein levels and protects cells against oxidative stress, also inhibits epithelial-tomesenchymal transition and metastasis of BC cells via focal adhesion kinase (FAK) expression (10). Lastly, the reported association between BC and PD may relate to abnormal estrogen metabolism. Women have a reduced PD risk compared with age-matched men, a phenomenon attributed by some researchers to the neuro-protective properties of estrogen in PD relevant neurons (11). Tamoxifen, a selective estrogen receptor (ER) modulator, given to patients with ER positive BC, has been reported to increase PD rates (12). Thus, in postmenopausal women, markedly reduced estrogen synthesis may both increase the risk of PD, and promote the expression of estrogen receptor genes in breast tissue to enhance BC risk of BC. Noteworthy this is a viable speculation that should be viewed as such.
In conclusion, the association between BC and the most common genetic forms of inherited PD cannot be accounted for by allele co-segregation at the genomic level. 
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